High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity

B cell receptor (BCR) sequencing is a powerful tool for interrogating immune responses to infection and vaccination, but it provides limited information about the antigen specificity of the sequenced BCRs. Here, we present LIBRA-seq (linking B cell receptor to antigen specificity through sequencing)...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cell Ročník 179; číslo 7; s. 1636
Hlavní autori: Setliff, Ian, Shiakolas, Andrea R, Pilewski, Kelsey A, Murji, Amyn A, Mapengo, Rutendo E, Janowska, Katarzyna, Richardson, Simone, Oosthuysen, Charissa, Raju, Nagarajan, Ronsard, Larance, Kanekiyo, Masaru, Qin, Juliana S, Kramer, Kevin J, Greenplate, Allison R, McDonnell, Wyatt J, Graham, Barney S, Connors, Mark, Lingwood, Daniel, Acharya, Priyamvada, Morris, Lynn, Georgiev, Ivelin S
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 12.12.2019
Predmet:
ISSN:1097-4172, 1097-4172
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:B cell receptor (BCR) sequencing is a powerful tool for interrogating immune responses to infection and vaccination, but it provides limited information about the antigen specificity of the sequenced BCRs. Here, we present LIBRA-seq (linking B cell receptor to antigen specificity through sequencing), a technology for high-throughput mapping of paired heavy- and light-chain BCR sequences to their cognate antigen specificities. B cells are mixed with a panel of DNA-barcoded antigens so that both the antigen barcode(s) and BCR sequence are recovered via single-cell next-generation sequencing. Using LIBRA-seq, we mapped the antigen specificity of thousands of B cells from two HIV-infected subjects. The predicted specificities were confirmed for a number of HIV- and influenza-specific antibodies, including known and novel broadly neutralizing antibodies. LIBRA-seq will be an integral tool for antibody discovery and vaccine development efforts against a wide range of antigen targets.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1097-4172
1097-4172
DOI:10.1016/j.cell.2019.11.003